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Overview of Aspergillus Allergens
R. Crameri, A. G. Glaser, M. Vilhelmsson, S. Zeller, and C. Rhyner
Abstract Fungi in general and, Aspergillus fumigatus (A. fumigatus) in particu-
lar, are able to produce complex patterns of IgE-binding molecules. Robotics-based
high throughput screening of A. fumigatus cDNA libraries displayed on phage sur-
faces revealed at last 81 different sequences encoding structures potentially able
to bind to serum IgE of sensitised individuals suffering from A. fumigatus-related
complications. Although not all of these allergens have been characterised in detail,
A. fumigatus still represents the best investigated allergenic source. A total of 23
A. fumigatus allergens are recorded by the official allergen list of the International
Union of Immunological Societies ( www.allergen.org ) and this is by far the longest
allergen list reported for a single allergenic source. The IgE-binding molecules
include species-specific as well as phylogenetically highly conserved cross-reactive
structures and such with unknown function. A subset of cDNAs have been used
to produce and characterise the corresponding recombinant allergens which have
proven to be useful diagnostic reagents allowing specific detection of A. fumigatus
sensitisation and differential diagnosis of allergic bronchopulmonary aspergillosis.
Structures highly conserved through different species like manganese-dependent
superoxide dismutase, P2 acidic ribosomal protein, cyclophilins and thioredoxins
induce, beyond sensitisation, IgE antibodies able to cross-react with the correspond-
ing homologous self-antigens. The frequently observed cross-reactivity is traceable
back to shared discontinuous B-cell epitopes as shown by detailed analyses of the
crystal structures.
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1 Introduction
In contrast to other allergenic sources like pollens or mites, which are primarily
associated with IgE-mediated type I allergic reactions, fungi are also associated with
a broad range of other partly life-threatening diseases [1]. Primary and secondary
fungal infections have become an important medical problem, concomitantly with
the increasing number of patients undergoing immunosuppressive medical treat-
ment, chemotherapy, and with increases in congenital and acquired immunodefi-
ciency [2]. Colonisation with fungi is a common finding. The spectrum of fungal
diseases in humans ranges from superficial skin infections, allergy and asthma,
to life-threatening diseases like invasive systemic mycoses or allergic bronchopul-
monary aspergillosis (ABPA) [3]. However, fungal infections rarely affect immuno-
competent hosts, and patients at high risk to be affected by fungal mycoses are
those with significant reduction in the number or function of granulocytes such as
leukaemia patients undergoing chemotherapy [4], patients on long-term treatment
with immunosuppressive drugs (e.g. organ transplant patients) [5], or patients under
high dosed steroid treatment [6]. The fatality rate of invasive mycoses is high and
the majority of the patients die despite of anti-mycotic treatment [7].
In contrast fungal allergy is rarely a life-threatening disease but the dimension
of the problem might be underestimated [8]. Three groups of fungi include most of
the species relevant for allergic disease: Zygomycota, Ascomycota, and Basidiomy-
cota. Allergens from these species are associated with fungal allergic asthma, sinusi-
tis, rhinitis, hypersensitivity pneumonitis, allergic bronchopulmonary mycoses and
atopic eczema [1]. However, recombinant allergens have so far only been reported
for the two groups Ascomycota and Basidiomycota (Table 1). Fungal allergy in gen-
eral (and allergy to A. fumigatus in particular) has been shown to be associated with
strong humoral responses to fungal antigens [2, 3]. Skin test surveys indicate that at
least 3–10% of the worldwide population might be affected by fungal sensitisation
[9]. Unfortunately the prevalence of fungal sensitisation has not yet been reliably
established because the available reports of skin test reactivity to fungi vary from 3
to 90% depending on the study population, the fungal species tested, and especially
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Table 1 Number of cloned fungal allergens and most prominent cross-reactive structures
Ascomycota Cloned allergens Pan-allergens
Alternaria alternate 10 Ribosomal P1 protein (Alt a 12); Ribosomal P2
protein (Alt a 5); Heat shock protein (Alt a 3);
Aldehyde dehydrogenase (Alt a 10)
Cladosporium
cladosporioides
1 Serine protease (Cla c 9)
Cladosporium
herbarum
8 Ribosomal P1 protein (Cla h 12); Ribosomal P2
progein (Cla h 5); Enolase (cla h 6); Serine protease
(Cla h 9); Aldehyde dehydrogenase (Cla h 10)
Curvularia lunata 3 Serine protease (Cur l 1); Enolase (Cur l 2);
Cytochrome c (Cur l 3)
Aspergillus flavus 1 Serine protease (Asp fl 13)
Aspergillus fumigatus 23 Peroxysomal protein (Asp f 3); MnSOD (Asp f 6);
Ribosomal P2 protein (Asp f 8); Heat shock protein
(Asp f 12); Serine proteases (Asp f 13, Asp f 18);
Enolase (Asp f 22); Cyclophilins (Asp f 11, Asp f
27); Thioredoxins (Asp f 28, Asp f 29)
Aspergillus niger 3 Serine protease (Asp n 18)
Aspergillus oryzae 2 Serine protease (Asp o 13)
Penicillium
brevicompactum
2 Serine protease (Pen b 13); Ribosomal P1 protein (Pen
b 26)
Penicillium
chrysogenum
5 Serine proteases (Pen ch 13, Pen ch 18)
Penicillium citrinum 7 Peroxysomal protein (Pen c 3); Serine protease (Pen c
3); Enolase (Pen c 22); Catalase (pen c 30)
Penicillium oxalicum 1 Serine protease (Pen o 18)
Fusarium culmorum 2 Ribosomal P2 protein (Fus c 1); Thioredoxin
homologous (Fus c 2)
Trichophyton rubum 2 Alkaline protease (Tri r 2); Serine protease (Tri r 4)
Trichophyton
tonsurans
2 Serine protease (Trit 4)
Candida albicans 2 Alcohol dehydrogenase (Cand a 1); Peroxysomal
protein (Cand a 2)
Candida boidinii 2 Peroxysomal membrane protein (Cand b 2)
Epicoccum
purpurascens
1 Serine protease (Epi p 1)
Basidiomycota
Coprinus comatus 5 Thioredoxin (Cop c 2)
Rhodotorula
mucilaginosa
2 Enolase (Rho m 1); Serine Protease (Rho m 2)
Psilocybe cubensis 2 Cyclophilin (Psi c 2)
Malassezia furfur 3 Peroxysomal membrane proteins (Mala f 2; Mala f 3)
Malassezia
sympodialis
10 Cyclophilin (Mala s 6); MnSOD (Mala s 11);
Thioredoxin (Mala s 13)
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from the fungal extract used [9, 10]. One of the major reasons for this huge varia-
tion is due to the fact that even commercially available fungal extracts used for skin
testing show an extremely high variation in their (major) allergen content [6, 7]. A
second important factor complicating the diagnosis of fungal allergy results from
an extended cross-reactivity detectable between different fungal species, which is
partly traceable back to the presence of structurally related allergens [11]. Cloning,
sequencing, and expression of these allergens as recombinant proteins and charac-
terisation of their cross-reactive profiles might contribute to considerably improve
this unsatisfactory situation.
2 The World of Fungal Allergens
During the past 20 decades an impressive number of allergens from different sources
have been cloned, sequenced, produced as recombinant proteins, and partly evalu-
ated for their diagnostic [10], and therapeutic value [12, 13]. Behind plant pollens
and mites with 184 and 164 reported single allergens, respectively, fungi with 100
allergens represent the third group of organisms from where the largest number of
allergens has been cloned and characterised (Table 1). The spectrum of fungal aller-
gens has been recently reviewed in detail, including also allergens reported in the
literature but not included in the official allergen nomenclature list [1]. According to
this work the fungal allergens cloned so far are 206. Of course as for the other aller-
genic sources not all cloned fungal allergens match to unique structures, because
cross-reactivity between homologous structures present in fungal extracts derived
from different species is a quite common phenomenon (Table 1).
Basically fungal allergens can be subdivided in species-specific allergens which
are specific to a species or at least to a genus [11] and phylogenetically highly con-
served structures which represent allergens showing cross-reactivity not only with
fungal proteins of many fungal species [14, 15], but also with homologous proteins
of other allergenic sources [16, 17], including human proteins [18].
3 The Allergen Repertoire of Aspergillus fumigatus
All fungal allergen repertoires described so fare are quite large, but those of A. fumi-
gatus is by far the most complex one. It spans at least 81 different cDNA gene
products ranging from 10 to more than 65 kDa in size [19], and 23 A. fumigatus
allergens are reported by the official allergen list (Table 2). The recently sequenced
29.4 megabase A. fumigatus genome contains 9,926 predicted genes [20, 21] indi-
cating that only a very small portion to the fungal proteins are able to induce a
switch towards production of specific IgE in B cells. However, the availability of the
complete genome sequence allowed to verify all reported cDNA sequences encod-
ing A. fumigatus allergens for consistency and for the presence of homologous and
orthologous allergens within the fungal kingdom [11, 22, 23]. The detailed compari-
son between genome sequence and published cDNA sequences [23] revealed several
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Table 2 Cloned Aspergillus fumigatus allergens ( www.allergen.org )
Allergen
Size
(kDa) CDS
Function/sequence
similarity
IgE-binding in
vitro (%)a SPT Access. no. References
Asp f 1 16.9 C Ribotoxin 66 pos. S889330 [34]
Asp f 2 37.0 C Unknown ND NT U56938 [78]
Asp f 3 18.5 C Peroxisomal 88 pos. U58050 [79]
protein
Asp f 4 30.0 P Unknown 42 pos. AJ001732 [45]
Asp f 5 42.1 C Metalloprotease 85 pos. Z30424 [27]
Asp f 6 23.0 C MnSOD 35 pos. U53561 [58]
Asp f 7 11.6 P Unknown 39 pos. AJ223315 [27]
Asp f 8 11.1 C P2 ribosomal
protein
10 pos. AJ224333 [59]
Asp f 9 32.3 P Unknown 66 pos. AJ223327 [27]
Asp f 10 34.4 C Aspartic protease 18 pos. X85092 [27]
Asp f 11 18.8 C Cyclophilin 50 pos. AJ006689 [60]
Asp f 12 65.0 P Heat shock protein ND NT U92465 [80]
Asp f 13 34.0 C Alkaline serine
protease
ND NT Z11580 [25]
Asp f 15 19.5 C Serine protease? 29 pos. AJ002026 [24]
Asp f 16 43.0 C Unknown ND NT G3643813 [26]
Asp f 17 19.4 P Unknown 43 pos. AJ224865 [24]
Asp f 18 34.0 C Vacuolar serine
protease
ND NT Y13338 [81]
Asp f 22 46.0 C Enolase ND NT AF284645 [82]
Asp f 23 44.0 C L3 ribosomal
protein
ND NT AF464911 [83]
Asp f 27 18.0 C Cyclophilin 75 pos. AJ937743 [30]
Asp f 28 11.9 C Thioredoxin 16 pos. AJ937744 [29]
Asp f 29 11.9 C Thioredoxin 26 pos. AJ937745 [29]
Asp f 34 19.3 C Phi A cell wall 94 pos. AM496018 Glaser et al.
protein (unpublished)
aIncidence amongst patients sensitised to A. fumigatus.
Legend: C, complete; CDS, coding sequences; ND, not determined; NT, not tested; pos., positive;
P, partial.
inconsistencies: (i) Asp f 15 [24] and Asp f 13 [25] are identical; (ii) Asp f 16 [26]
does not appear to be encoded by the A. fumigatus AF293 genome but shows a high
degree of homology with Asp f 9 [27], which is present in the genome. Therefore
it can be concluded that the Asp f 9 cDNA sequence is correct, and that the pub-
lished Asp f 16 peptide sequence results from frameshift, other sequencing errors,
or derives from a different A. fumigatus strain; (iii) Asp f 17, originally described
as a cDNA encoding a 191 amino acid protein [24], is incomplete and the com-
plete gene encodes a protein of 284 amino acids; and (iv) the postulated sequence of
the Asp f 56 kDa allergen not included in the official allergen database, which was
derived from a short peptide obtained from a biochemically purified protein [28] is
not predicted to be encoded in any of the sequenced Aspergillus genomes.
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All other A. fumigatus allergens reported in the official allergen database as well
as the sequences of the recently cloned thioredoxins (Asp f 28, Asp f 29) [29],
cyclophilins (Asp f 11, Asp f 27) [30], and Phi A cell wall protein (Asp f 34,
Glaser unpublished) sequences showed virtually a 100% identity with the genome
sequence, confirming at genomic level the validity of cDNA cloning approaches for
the elucidation of allergen repertoires. The whole repertoire of A. fumigatus aller-
gens included in the official allergen list reported in Table 2 have been produced as
highly pure recombinant allergens and evaluated for their IgE-binding capacity in
vitro. The majority of these proteins have also been tested for their ability to elicit
positive skin tests in vivo [27, 29–32].
Although these detailed clinical investigations clearly show that the cloned
cDNA sequences encode biologically active and clinically relevant allergens, the
reason for the allergenicity of these specific proteins remains unknown. Even the
solution of the three dimensional structure of an array of fungal allergens (Table 3),
and intensive modelling approaches based on homologous structures (Table 4), have
not yet contributed to understand the reasons why some proteins are able to induce
a switch to allergen-specific IgE production and some others are not [15, 33].
Table 3 Solved crystal structures of fungal allergen
Allergen Size (kDa) Basic structure Coordinatesa References
Asp f 1 (A. fumigatus) 16.9 Ribotoxin 1ONE [84]
Asp f 6 (A. fumigatus) 23 MnSOD 1KKC [65]
Asp f 11 (A. fumigatus) 13.7 Cyclophilin 2C3B [61]
Mala s 1 (M. sympodialis) 22.9 Unknown function 1ABM [67]
Mala s 6 (M. sympodialis) 17.2 Cyclophilin 2CFE [30]
Mala s 13 (M. sympodialis) 11.9 Thioredoxin 2J23 [29]
aPDB-coordinates of the structure.
Table 4 Modelled fungal allergen structures
Allergen Size (kDa) Basic structure Coordinatesa References
Cla h 6 (C. herbarum) 47.5 Enolase 1ONE [85]
NTF 2 (C. herbarum) 14.2 Nuclear transport factor 2 1 OUN [86]
Cla h 8 (C. herbarum) 8.1 Cold shock protein 3MFE [87]
NTF 2 (A. alternata) 13.7 Nuclear transport factor 2 1OUN [86]
MnSOD (S. cerevisiae) 22.9 MnSOD 1ABM [65]
Asp f 22 (A. fumigatus) 46 Enolase 4ENL [11]
Asp f 27 (A. fumigatus) 18 Cyclophilin 2CFE
Glaser et al.
(unpublished)
Asp f 28 (A. fumigatus) 11.9 Thioredoxin 2TRX
Glaser et al.
(unpublished)
Asp f 29 (A. fumigatus) 11.9 Thioredoxin 2J23
Glaser et al.
(unpublished)
Pen ch 18 (chrysogenum) Serine protease 1IC6A [11]
aPDB-coordinates of the structure used for modelling.
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Beside Asp f 4, Asp f 7 Asp f 9 and Asp f 16 which lack to show a relevant
sequence similarity to proteins deposited in the Swissprot database, all but one aller-
gen show extended sequence similarities with known fungal and non-fungal pro-
teins (Table 2). The exception is Asp f 1, a potent fungal ribotoxin which was the
first fungal allergen cloned [34] and the first recombinant allergen tested in humans
at all [31]. Asp f 1 reveals sequence identity to restrictocin, an 18 kDa ribotoxin
produced by Aspergillus restrictus never described as allergen [35] that is >99%
identical to Asp f 1 sequences derived from different clinical isolates of A. fumigatus
[36, 37]. All these 18 kDa proteins are related to ribotoxins such as α-sarcin [38] and
mitogillin [39]. They represent the most potent ribonucleolytic enzymes found in
nature [40, 41] and are restricted to the genus Aspergillus as recently demonstrated
by a genome wide analysis involving all fungal genomes sequenced so far [11].
4 Diagnostic Value of Recombinant A. fumigatus Allergens
As already mentioned allergen extracts, and in particular A. fumigatus extracts, are
complex mixtures of allergenic and non allergenic proteins and as such difficult to
standardise [42]. The best example thereof is delivered by a skin test study with four
different commercially available A. fumigatus extracts conducted in cystic fibrosis
patients sensitised to A. fumigatus [43]. This study shows that none of the four tested
commercial extracts is able to detect all of the 31 A. fumigatus-sensitised patients
in skin prick test, clearly demonstrating that the diagnostic result strongly depends
on the quality of the extract used. An additional complication in the diagnosis of
A. fumigatus sensitisation results from the fact that the extracts immobilised on the
ImmunoCAP system, which is still considered as the “golden standard” for the in
vitro detection of A. fumigatus-sensitisation, is not available for skin prick tests
(the author is referred to the chapter on Aspergillus IgE testing, in this book). This
fact might partly explain the huge discrepancy between skin prick test and in vitro
incidence of the prevalence of A. fumigatus sensitisation reported in the literature,
because both methods depend on the quality of the used extracts. In contrast, recom-
binant allergens can be produced as perfectly standardised protein preparations [44].
As shown in Table 2, rAsp f 1, 3, 4–11, 15, 17, 27–29, and 34 have been investigated
in skin test studies. The experience accumulated performing skin tests and serology
with different recombinant A. fumigatus allergens involving more than 600 indi-
viduals suffering from various A. fumigatus-related diseases and over 100 healthy
controls allows to draw the following firm conclusions: (i) only individuals with
detectable serum IgE levels against a tested recombinant allergen showed positive
skin test reactions with the specific allergen [44]; (ii) the overall positive skin test
response of individuals sensitised to A. fumigatus extracts to recombinant allergens
are highly variable from allergen to allergen ranging from around 70% for the major
allergen rAsp f 1 [27] to a few percentage for minor allergens like Asp f 8 or Asp
f 10 [24]; (iii) no reactivity to any of the recombinant allergens could be detected
in any of the more than 100 healthy controls tested; (iv) rAsp f 4 and rAsp f 6
are predominantly recognised by patients suffering from ABPA [32, 45, 46]; (v) no
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discrepancy between serology and skin test results based on recombinant allergens
could be detected in any of the subjects tested [44]; and (vi) the recombinant aller-
gens can be immobilised to ImmunoCAPs without loss of specificity or sensitivity
allowing a fully automated serologic diagnosis of sensitisation against each single
allergen [32, 47, 48], and thus a component-resolved diagnosis of allergic conditions
related to A. fumigatus sensitisation.
Notably, skin tests and serologic investigations showed that two recombinant
allergens, Asp f 4 and Asp f 6, can be used to confirm or reject an ABPA suspected
from clinical signs [32, 45, 46, 49, 50]. ABPA is a clinical syndrome that is difficult
to diagnose, especially in patients suffering from cystic fibrosis [51], which should
be excluded in all individuals sensitised to A. fumigatus to avoid an irreversible
deterioration of the lung function [52].
5 Cross- and Autoreactivity
Many of the A. fumigatus allergens cloned, characterised, produced, and evaluated
for their allergenicity in vivo (Table 2) represent phylogenetically-conserved pro-
teins widespread in basically every living organism. The presence of cross-reactive
structures like enolase and MnSOD, which are also described as latex allergens
[16, 17], cyclophilin known as a birch pollen allergen [53], thioredoxin described
as a prominent food allergen [54], and serine proteases which play an important
role in house dust mite allergy [55] indicate that the whole repertoire of allergenic
molecules is highly redundant and, thus, limited to a discrete number of structures
[56]. In contrast to polysensitisation which is easy to demonstrate by simple deter-
mination of the RAST values against different allergen extracts [8], cross-reactivity
between fungal extracts is a poorly investigated phenomenon which, however, could
contribute to a better understanding of polysensitisation. Basically cross-reactivity
can be traced back to conserved proteins sharing common B and T cell epitopes
as shown for many allergen structures [33]. Amongst these MnSOD (Asp f 6) [57,
58], P2 acidic ribosomal protein (Asp f 8) [59], cyclophilins (Asp f 11 and Asp f 27)
[30, 60, 61] and thioredoxins (Asp f 28 and Asp f 29) [29] have been shown to
belong to families of cross-reactive pan-allergens. Per definition pan-allergens share
a high degree of sequence identity at primary structure level, thus belonging to pro-
tein families showing similar structural folding [33, 62]. Interestingly some of these
proteins show cross-reactivity also with their homologous human proteins at both,
humoral and cellular level. The best investigated structures at this level are human
MnSOD [57, 58], cyclophilin [30, 61] and thioredoxin [29], which were shown to
bind to serum IgE from A. fumigatus sensitised patients in vitro, to elicit specific skin
test reactions in vivo, and to be potentially involved in the pathogenesis of ABPA
and atopic eczema [18, 63]. Although the role played by IgE-mediated autoreac-
tivity to self-antigens remains controversial, the fact that the application of human
MnSOD in patch test on healthy skin areas of atopic eczema patients sensitised to
fungal MnSOD is sufficient to induce an eczematous reaction [57, 63] strongly indi-
cates that autoreactivity could contribute to the exacerbation of the symptoms in the
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absence of external exposure to environmental allergens. For self-antigens show-
ing a high degree of sequence identity/homology to environmental allergens, these
reactions can be clearly explained by cross-reactive IgE antibodies primarily raised
against external allergens. However, also self-antigens without sequence homology
with any known allergen but able to bind serum IgE from atopic eczema patients
have been described [64]. For these structures it is still not clear if they are able to
directly induce a B cell switch to IgE production, or if the observed IgE-binding
capability is due to cross-reactivity with not yet identified environmental allergen
structures [18].
6 Structural Aspects of Fungal Allergens
The list of known allergen crystal structures with coordinates deposited in the Pro-
tein Data Bank (PDB, http://www.rcsb.org/pdb/) report about 40 structures. The
best investigated allergenic source in structural terms is the timothy grass Phleum
pratense where five structures have been solved, followed by profilins of differ-
ent species [15]. However, only three crystal structures derived from fungal aller-
gens, ribotoxin (Asp f 1) [45, 46], MnSOD (Asp f 6) [65] from A. fumigatus and a
Xylanase from Paecilomyces variotii [66] have been reported so far. Recently the
crystal structures of a cyclophilin of A. fumigatus (Asp f 11) [61] and Malassezia
sympodialis (M. sympodialis) (Mala s 6) [30], as well as the crystal structure of
thioredoxin of M. sympodialis (Mala s 13) [29], and Mala s 1, a major allergen of M.
sympodialis with unknown function [67] have been determined at high resolution.
These structures are per se not new, nor are the solved allergen crystal structures
in general [62]. Therefore it is unlikely that crystal structures will help us to progress
in our understanding of the basic immunologic mechanisms leading to allergy. In
contrast, elucidation of the 3D structure of allergens has essentially contributed to
our understanding of cross-reactivity amongst homologous structures derived from
phylogenetically distant allergen sources [29, 30, 68]. Based on the coordinates of a
known homologous crystal structure of a sufficiently homologous protein it is easy
to model a structure starting from the known amino acid sequence of an allergen
(Table 3) and this work will strongly contribute to predict fungal proteins that have
the potential to be allergens derived from comparative genomic approaches [11].
Progress in this field will have a strong impact for understanding fungal sensiti-
sation, cross-reactivity, interpretation of diagnostic outcomes and management of
fungal allergy.
7 Therapy of Fungal Allergy
Severe symptoms due to fungal sensitisation, especially in patients with ABPA, are
usually treated with systemic steroids [69]. The discussion on the benefits of antifun-
gal therapy for these patients is beyond the scope of this article. Allergen-specific
immunotherapy, the only treatment able to cure allergy, is not recommended for
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mould allergy because standardised extracts are not available [70], and because the
therapy is associated with frequent occurrence of severe side effects [71]. In fact
only a few studies describing immunotherapy with fungal extracts are available from
the literature. The use of recombinant allergens for allergen-specific immunother-
apy is claimed to solve problems related to the standardisation of extracts [72, 73].
Indeed some studies report the successful immunotherapy of pollen allergic patients
with recombinant allergens [12, 74–76]. Therefore, the use of recombinant aller-
gens for the immunotherapy of fungal allergies may be a future aim [1]. However,
in view of the large number of allergens produced by fungi it is questionable if such
an approach will be feasible, especially if the financial aspects for the production of
cGMP conform multi-component vaccines based on single recombinant allergens
are considered [77].
8 Conclusions
There is no doubt that A. fumigatus plays a relevant role in invasive aspergillo-
sis as well as in many forms of allergy. Amongst the A. fumigatus-related aller-
gic complications ABPA is, although infrequent, the most severe one, and should
be ruled out in all asthmatic and cystic fibrosis patients sensitised to the fungus
to avoid irreversible deterioration of the lung function. The diagnosis of ABPA
is challenging as it is based on distinct clinical and laboratory findings that are
rarely present at the same time during the different phases of the disease. Amongst
the laboratory findings serology is of outmost importance for the diagnosis of
ABPA, although strongly limited by the quality of the extracts used. Cloning,
expression, characterisation, and production of recombinant A. fumigatus aller-
gens have contributed to improve a component resolved diagnosis of the disease.
Large scale serological studies showed that specific IgE responses to at least four
A. fumigatus allergens (Asp f 2, 4, 6, and 8) are quite specific for ABPA. These
disease-specific allergens allow a serological discrimination between ABPA and
A. fumigatus-sensitisation with almost 100% specificity and around 90% sensitiv-
ity. Such discrimination is not possible using conventional fungal extracts, high-
lighting the potential of recombinant allergens for diagnostic purposes. However, to
reconstruct the whole allergenicity of the fungal extract, more of the IgE-binding
cDNA sequences identified by high-throughput phage surface display screenings
need to be cloned and used to produce and clinically evaluate the encoded recombi-
nant allergens. The availability of the complete A. fumigatus genome sequence will
facilitate this task and in addition contribute to identify cross-reactive IgE-binding
proteins widespread among the fungal kingdom. Together with the rapidly grow-
ing knowledge about 3D structures a complete allergen repertoire will allow to gain
deep knowledge about the role of each single structure in the pathophysiology of
ABPA and, perhaps, to develop a panel of allergens for the immunotherapy of the
disease.
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